Top News

Mark Cuban Aims To Disrupt A $365 Billion Industry – With The Only Startup That Bears His Name

Panorama of a city business district with office buildings and skyscrapers and superimposed data, charts and diagrams related to stock market, currency exchange and global finance. Blue line graphs with numbers and exchange rates, candlestick charts and financial figures fill the image with a glowing light. Sunset light.

S&P 500




Dow 30








Russell 2000




Crude Oil
















10-Yr Bond
















CMC Crypto 200




FTSE 100




Nikkei 225




Billionaire venture capitalist Mark Cuban has founded or invested early in hundreds of startup companies over the years. But only one of them, founded in January 2022, bears his name.

The Mark Cuban Cost Plus Drug Co. seeks to disrupt the $365 billion U.S. prescription drug market, which is rife with pricing inefficiencies. For example, one tablet of the Type 2 diabetes treatment Metformin costs over $500 at retail prices. But through Cuban’s company, the same tablet is just $46.20.

The company offers 350 prescription drugs at cost, plus a fixed 15% margin that still makes some prescription drugs significantly cheaper than their retail prices. The savings are made possible in part by eliminating the middleman in the prescription drug industry: Cuban’s company bypasses health insurers to negotiate directly with drug manufacturers.

The startup could have saved Medicare up to $3.6 billion in 2020 alone, according to a study by Harvard Medical School. But as significant as that number is, it pales in comparison to an even lower-hanging fruit in the fight to drive down healthcare costs: targeting the nationwide stress epidemic.

To stay updated with top startup investments, sign up for Benzinga’s Startup Investing & Equity Crowdfunding Newsletter

Stress costs the U.S. economy as much as $300 billion per year, according to the American Psychological Association. A huge source of this is healthcare costs, with 65% of households reporting high levels of stress or anguish over treatment costs. Cuban’s company, should it succeed in slashing prescription drug prices across the board, could provide tremendous relief on this front.

But one startup is tackling stress directly. Founded in 2019, Sensate is the company behind a patented relaxation device that it says is the first of its kind. The novel patented technology uses infrasonic therapy to help the body’s nervous system recover from daily stresses.

Sensate grew revenue by 363% from 2020 to 2021, when it hit $2.8 million in revenue. Prominent venture capital backers include TenOneTen, Unlock Venture Partners and Expert DOJO.

See more on startup investing from Benzinga.

Never Lose Your Things Again – The Startup Pouring Gasoline on the Apple AirTag

Martin Tobias Invested in Google, DocuSign, OpenSea and Over a Dozen Other Unicorns – Here’s What Startup He Is Investing in Next and How to Invest Alongside Him

Don’t miss real-time alerts on your stocks – join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article originally appeared on

© 2023 Benzinga does not provide investment advice. All rights reserved.


Billionaires Worth $123 Billion Buy Stake In Kushner’s Thrive

Previous article

Microsoft Second-Quarter Earnings Live Blog

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Top News